Pessary use fails to reduce adverse neonatal outcomes in twin pregnancies with short cervix

Written By :  Dr. Shravani Dali
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2022-08-08 12:00 GMT   |   Update On 2022-08-08 12:07 GMT

Use of Arabian Pessary fails to significantly reduce adverse neonatal outcomes in twin pregnancies with a short cervix, according to a recent study published in the American Journal of Obstetrics & Gynecology. The number of twin pregnancies continues to increase worldwide as both the number of pregnancies obtained by medically assisted reproduction and age at first pregnancy...

Login or Register to read the full article

Use of Arabian Pessary fails to significantly reduce adverse neonatal outcomes in twin pregnancies with a short cervix, according to a recent study published in the American Journal of Obstetrics & Gynecology.

The number of twin pregnancies continues to increase worldwide as both the number of pregnancies obtained by medically assisted reproduction and age at first pregnancy keep rising. Preterm delivery is the major complication associated with twin pregnancies. The effectiveness of preventive treatments such as progesterone or cervical cerclage for women with a short cervix is doubtful in twin pregnancies. The effectivity of cervical pessaries in preventing preterm birth and its associated morbidity and mortality is also controversial.

A study was conducted to seek to investigate if the Arabin pessary reduces adverse neonatal outcomes in twin pregnancies with a short cervix.

This open-label, multicenter, randomized controlled trial on twin pregnancies with a cervical length of <35 mm compared pessary placement at 16+0 to 24+0 weeks gestation with standard care alone. The primary endpoint was a composite of adverse neonatal outcomes, namely peripartum or neonatal death or significant neonatal morbidity before hospital discharge, defined as at least 1 of the following complications: bronchopulmonary dysplasia, intraventricular haemorrhage grade III to IV, periventricular leukomalacia, necrotizing enterocolitis grade II or higher, culture-proven sepsis, and retinopathy requiring treatment. A sample size of 308 pregnancies was planned to ensure 80% power to compare the proportions of women with at least 1 infant with an adverse neonatal outcome. The intention-to-treat analysis after multiple imputations of missing data was supplemented with a secondary analysis that controlled for gestational age and cervical length, both at inclusion. The primary endpoint was also compared between randomization groups in the per-protocol population, which excluded patients with prespecified major protocol violations (mostly cervical cerclage and/or progesterone after inclusion). Secondary endpoints included preterm birth, spontaneous preterm birth, and pessary side effects.

Results:

  • In total, 315 women were randomized to either receive a pessary (n=157) or standard management (n=158). Overall, 10.8% (34 women) of participants had a missing value for the primary endpoint, mostly (79%) because of the lack of paternal consent for neonatal data collection.
  • In the intention-to-treat analysis, the adverse neonatal outcome occurred in 16.8% of the pessary group vs in 22.5% of the control group
  • The per-protocol analysis did not show any significant difference between groups
  • The occurrence of preterm birth or spontaneous preterm birth did not differ significantly between groups.
  • No serious side effects were associated with pessary use.

Thus, pessary use in the study did not significantly reduce adverse neonatal outcomes in twin pregnancies with a short cervix.

Reference:

Marion Groussolles et al. Arabin pessary to prevent adverse perinatal outcomes in twin pregnancies with a short cervix: a multicenter randomized controlled trial (PESSARONE). February 02, 2022 DOI: https://doi.org/10.1016/j.ajog.2022.01.038



Tags:    
Article Source : American Journal of Obstetrics & Gynecology

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News